The PD-L1 antibody MPDL3280A displayed antitumor activity across a range of cancer types, including lung, kidney, colon and stomach cancers. MPDL3280A was well tolerated. Phase I study results demonstrated no limiting toxicities. WASHINGTON, D.C. —...
Filed under: Press Releases, Research, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, 2013 Annual Meeting, Dr. Michael S. Gordon, MPDL3280A, PD-L1, engineered antibody, death-ligand 1